Muscle spasticity is a condition characterized by involuntary muscle stiffness and spasms, often resulting from neurological disorders such as stroke, multiple sclerosis, or cerebral palsy. According to Andrew Harb et al., 2025, it accounts for a significant burden in post-stroke rehabilitation, affecting approximately 42.6% of stroke patients, with severe cases in 15.6%. The pipeline features promising therapies like Daxxify (daxxibotulinumtoxinA-lanm) by Revance Therapeutics. According to the Muscle Spasticity Pipeline Analysis by Expert Market Research, the market is witnessing growing focus on neurotoxin-based therapies, with advancements in targeted drug delivery expected to drive growth in the coming years.
Major companies involved in the muscle spasticity pipeline analysis include Merz Pharmaceuticals GmbH, Celgene, and others.
Leading drugs currently in the pipeline include IPN10200, MTR-601, and others.
The growth of the muscle spasticity pipeline is driven by rising neurological disorder prevalence, increased R&D investments in GABA-modulating therapies, and expanding clinical trials targeting pediatric and post-stroke spasticity.
The Muscle Spasticity Pipeline Analysis Report by Expert Market Research gives comprehensive insights into muscle spasticity therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for muscle spasticity. The muscle spasticity report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The muscle spasticity pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with muscle spasticity treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to muscle spasticity.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Muscle spasticity is a condition marked by involuntary muscle stiffness or tightness. It can be caused by disrupted nerve signals between the brain and muscles and commonly occurs due to neurological disorders such as multiple sclerosis, cerebral palsy, or spinal cord injuries, where damaged nerve pathways trigger excessive muscle contractions, limiting movement and causing discomfort or pain.
Muscle spasticity treatment focuses on reducing stiffness and improving mobility. Common therapies include oral medications, injections, physical therapy, and intrathecal drug delivery systems. In the muscle spasticity drug pipeline, Baclofen (brand names: Gablofen®, Lyvispah™, Fleqsuvy™) is frequently explored. It targets the central nervous system to relieve spasms, enhance muscle movement, and reduce pain in patients with multiple sclerosis.
Muscle spasticity is a common condition following neurological events. According to Andrew Harb et al., 2025, 42.6% of stroke patients developed spasticity, with 15.6% experiencing severe forms. In cerebral palsy, spastic subtypes were observed in 90% of cases. Long-term data also show that 20% to 30% of post-stroke patients exhibit increased muscle tone, including spasticity and contractures, even seven years after the initial stroke.
This section of the report covers the analysis of muscle spasticity drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The muscle spasticity pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II accounts for 33.33%, covers a major share of the total muscle spasticity clinical trials. Phase III holds 23%, followed by phase I at 20%, and early phase I at 15%. This balanced distribution supports continuous innovation, suggesting promising future therapies and a positive impact on market expansion.
The drug molecule categories covered under the muscle spasticity pipeline analysis include small molecule, cell therapy, polymer, gene therapy, and peptides. The muscle spasticity report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for muscle spasticity. Cannabis-based therapies are also gaining momentum in the muscle spasticity drug pipeline. For instance, Nabiximols (Sativex), a botanical extract containing tetrahydrocannabinol and cannabidiol in a 1:1 ratio, is under evaluation for managing spasticity associated with multiple sclerosis. Delivered as an oromucosal spray, it modulates cannabinoid receptors to relieve stiffness, spasms, and related neuropathic pain.
The EMR report for the muscle spasticity pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed muscle spasticity therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in muscle spasticity clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for muscle spasticity. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of muscle spasticity drug candidates.
IPN10200 is being sponsored by Ipsen and is currently undergoing an integrated Phase I/II clinical trial to evaluate its safety and efficacy in adults with upper limb spasticity. This study aims to assess the pharmacodynamic profile of IPN10200 and determine the optimal dose for reducing muscle stiffness. IPN10200, a novel botulinum toxin-based therapy, is being compared against Dysport and placebo to establish its clinical benefit and tolerability.
MTR-601, developed by Motric Bio, is currently undergoing Phase I trials for muscle spasticity. The objective of this phase is to evaluate the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. MTR-601 is an orally administered selective skeletal myosin-2 inhibitor, aiming to reduce excessive muscle contraction. Motric Bio is focusing on advancing novel spasticity treatments through targeted myosin inhibition.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Muscle Spasticity Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for muscle spasticity. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into muscle spasticity collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share